AGN 195795

Drug Profile

AGN 195795

Alternative Names: AC 170472

Latest Information Update: 12 Jul 2007

Price : $50

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Eye disorder therapies
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 12 Jul 2007 Discontinued - Phase-I/II for Glaucoma in USA (unspecified route)
  • 17 May 2006 No development reported - Phase-I/II for Glaucoma in USA (unspecified route)
  • 25 Aug 2003 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top